The company plans to expand its pharmaceutical pipeline through multiple channels, including internal research, in-licensing, M&A and partnerships. Rather than an integrated commercialization model covering the introduction of specific candidate products through clinical development and out-licensing, the focus is on strategies for sourcing and expanding the pipeline.